Analysis of chemical and biological features yields mechanistic insights into drug side effects.

Side effects (SEs) are the unintended consequence of therapeutic treatments, but they can also be seen as valuable readouts of drug effects, resulting from the perturbation of biological systems by chemical compounds. Unfortunately, biology and chemistry are often considered separately, leading to incomplete models unable to provide a unified view of SEs. Here, we investigate the molecular bases of over 1,600 SEs by navigating both chemical and biological spaces. We identified characteristic molecular traits for 1,162 SEs, 38% of which can be explained using solely biological arguments, and only 6% are exclusively associated with the chemistry of the compounds, implying that the drug action is somewhat unspecific. Overall, we provide mechanistic insights for most SEs and emphasize the need to blend biology and chemistry to surpass intricate phenomena not captured in the molecular biology view.

[1]  Tudor I. Oprea,et al.  Chemography: the Art of Navigating in Chemical Space , 2000 .

[2]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[3]  Scott Boyer,et al.  Correction: Automatic Filtering and Substantiation of Drug Safety Signals , 2012, PLoS Computational Biology.

[4]  P. Aloy,et al.  Interactome mapping suggests new mechanistic details underlying Alzheimer's disease. , 2011, Genome research.

[5]  L. Becquemont,et al.  Pharmacogenomics of adverse drug reactions: practical applications and perspectives. , 2009, Pharmacogenomics.

[6]  Peter Ertl,et al.  Mining for Bioactive Scaffolds with Scaffold Networks: Improved Compound Set Enrichment from Primary Screening Data , 2011, J. Chem. Inf. Model..

[7]  Scott Boyer,et al.  Ligand-Based Approach to In Silico Pharmacology: Nuclear Receptor Profiling , 2006, J. Chem. Inf. Model..

[8]  W. Arnold,et al.  Xanthopsia and van Gogh's yellow palette , 1991, Eye.

[9]  Stefan Wetzel,et al.  Interactive exploration of chemical space with Scaffold Hunter. , 2009, Nature chemical biology.

[10]  R. Sharan,et al.  PREDICT: a method for inferring novel drug indications with application to personalized medicine , 2011, Molecular systems biology.

[11]  F. Nantel,et al.  Bradykinin B1 receptor antagonist R954 inhibits eosinophil activation/proliferation/migration and increases TGF-β and VEGF in a murine model of asthma , 2010, Neuropeptides.

[12]  A. Fura,et al.  Role of pharmacologically active metabolites in drug discovery and development. , 2006, Drug discovery today.

[13]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[14]  Daphne Koller,et al.  Systematic analysis of genome-wide fitness data in yeast reveals novel gene function and drug action , 2010, Genome Biology.

[15]  Doheon Lee,et al.  Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.

[16]  João D. Ferreira,et al.  Semantic Similarity for Automatic Classification of Chemical Compounds , 2010, PLoS Comput. Biol..

[17]  Chris Morley,et al.  Open Babel: An open chemical toolbox , 2011, J. Cheminformatics.

[18]  P. Holzer.  Opioid receptors in the gastrointestinal tract , 2009, Regulatory Peptides.

[19]  R. Solé,et al.  Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.

[20]  J. Gies,et al.  Kinins and respiratory tract diseases. , 1993, The European respiratory journal.

[21]  Azeem Majeed,et al.  Ten-year trends in hospital admissions for adverse drug reactions in England 1999–2009 , 2010, Journal of the Royal Society of Medicine.

[22]  Yoshihiro Yamanishi,et al.  Predicting drug side-effect profiles: a chemical fragment-based approach , 2011, BMC Bioinformatics.

[23]  R. Altman,et al.  Data-Driven Prediction of Drug Effects and Interactions , 2012, Science Translational Medicine.

[24]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2011 , 2010, Nucleic Acids Res..

[25]  Tudor I. Oprea,et al.  iPHACE: integrative navigation in pharmacological space , 2010, Bioinform..

[26]  Damian Szklarczyk,et al.  STITCH 3: zooming in on protein–chemical interactions , 2011, Nucleic Acids Res..

[27]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[28]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[29]  Christoph Steinbeck,et al.  Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..

[30]  D. Gurwitz,et al.  'Drug reactions, enzymes, and biochemical genetics': 50 years later. , 2007, Pharmacogenomics.

[31]  J. Clayton-Smith,et al.  Xq28 duplication presenting with intestinal and bladder dysfunction and a distinctive facial appearance , 2009, European Journal of Human Genetics.

[32]  Seth I. Berger,et al.  Role of systems pharmacology in understanding drug adverse events , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.

[33]  Thomas C. Wiegers,et al.  The Comparative Toxicogenomics Database: update 2013 , 2012, Nucleic Acids Res..

[34]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[35]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[36]  Phillip W. Lord,et al.  Semantic Similarity in Biomedical Ontologies , 2009, PLoS Comput. Biol..

[37]  Ben Y. Reis,et al.  Predicting Adverse Drug Events Using Pharmacological Network Models , 2011, Science Translational Medicine.

[38]  J. Wallace,et al.  Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. , 2002, Blood.

[39]  Thomas Lengauer,et al.  Improved scoring of functional groups from gene expression data by decorrelating GO graph structure , 2006, Bioinform..

[40]  G. Román,et al.  Disorders of neuromuscular transmission due to natural environmental toxins , 1992, Journal of the Neurological Sciences.

[41]  R. Krauss,et al.  When good drugs go bad , 2007, Nature.

[42]  Navdeep Jaitly,et al.  A Structure-Based Approach for Mapping Adverse Drug Reactions to the Perturbation of Underlying Biological Pathways , 2010, PloS one.

[43]  A. Vedani,et al.  VirtualToxLab - a platform for estimating the toxic potential of drugs, chemicals and natural products. , 2012, Toxicology and applied pharmacology.

[44]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[45]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[46]  P. Goldman-Rakic,et al.  Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  Dominic P. Williams,et al.  Idiosyncratic toxicity: the role of toxicophores and bioactivation. , 2003, Drug discovery today.

[48]  J. Sosna,et al.  Raloxifene attenuates Gas6 and apoptosis in experimental aortic valve disease in renal failure. , 2011, American journal of physiology. Heart and circulatory physiology.

[49]  Relevance of animal models to human tardive dyskinesia , 2012, Behavioral and Brain Functions.

[50]  P. Angel,et al.  The catalytic domain of activated collagenase I (MMP-1) is absolutely required for interaction with its specific inhibitor, tissue inhibitor of metalloproteinases-1 (TIMP-1). , 1997, European journal of biochemistry.

[51]  B. Tune,et al.  Mechanisms of cephalosporin nephrotoxicity: a comparison of cephaloridine and cephaloglycin. , 1980, Kidney international.

[52]  中尾 光輝,et al.  KEGG(Kyoto Encyclopedia of Genes and Genomes)〔和文〕 (特集 ゲノム医学の現在と未来--基礎と臨床) -- (データベース) , 2000 .

[53]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[54]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[55]  M. Milik,et al.  Mapping adverse drug reactions in chemical space. , 2009, Journal of medicinal chemistry.